Role of P-glycoprotein in the hepatic metabolism of tacrolimus

Xenobiotica

Volumn 36, Issue 1, 2006, Pages 1-13

  Jeong, H ^a   Chiou, W L ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Hepatic metabolism; Liver perfusion; Membrane transport; P glycoprotein

Indexed keywords

CYTOCHROME P450 3A4; ELACRIDAR; GLYCOPROTEIN P; TSUKUBAENOLIDE; VERAPAMIL;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; LIVER; LIVER CLEARANCE; LIVER METABOLISM; MALE; METABOLIC CLEARANCE RATE; MODULATION; NONHUMAN; PROTEIN FUNCTION; PROTEIN INTERACTION; RAT;

ACRIDINES; ANIMALS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPATOCYTES; IMMUNOSUPPRESSIVE AGENTS; LIVER; MALE; METABOLIC CLEARANCE RATE; P-GLYCOPROTEIN; RATS; RATS, SPRAGUE-DAWLEY; TACROLIMUS; TETRAHYDROISOQUINOLINES;

ANIMALIA;

EID: 33644611576     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250500485115     Document Type: Article

References (26)

1. Achira M, Suzuki H, Ito K, Sugiyama Y. 1999. Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P4503A4. AAPS PharmScience 1:E18.
2. Annaert PP, Turncliff RZ, Booth CL, Thakker DR, Brouwer KL. 2001. P-glycoprotein-mediated in vitro biliary excretion in sandwich-cultured rat hepatocytes. Drug Metabolism and Disposition 29:1277-1283.
3. Booth CL, Brouwer KR, Brouwer KL. 1998. Effect of multidrug resistance modulators on the hepatobiliary disposition of doxorubicin in the isolated perfused rat liver. Cancer Research 58:3641-3648.
4. Brouwer KL, Thurman RG. 1996. Isolated perfused liver. Pharmacology and Biotechnology 8:161-192.
5. Chiou WL, Chung SM, Wu TC. 2000a. Apparent lack of effect of P-glycoprotein on the gastrointestinal absorption of a substrate, tacrolimus, in normal mice. Pharmacology Research 17:205-208.
6. Chiou WL, Chung SM, Wu TC. 2000b. Potential role of P-glycoprotein in affecting hepatic metabolism of drugs. Pharmacology Research 17:903-905.
7. Chiou WL, Chung SM, Wu TC, Ma C. 2001. A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans. International Journal of Clinical Pharmacology and Therapy 39:93-101.
8. Christians U, Jacobsen W, Serkova N, Benet LZ, Vidal C, Sewing KF, Manns MP, Kirchner GI. 2000. Automated, fast and sensitive quantification of drugs in blood by liquid chromatography-mass spectrometry with on-line extraction: Immunosuppressants. Journal of Chromatography B: Biomedical and Science Applications 748:41-53.
9. Cummins CL, Wu CY, Benet LZ. 2002. Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clinical and Pharmacology Therapy 72:474-489.
10. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. 1999. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metabolism and Disposition 27:866-871.
11. Davies B, Morris T. 1993. Physiological parameters in laboratory animals and humans. Pharmacology Research 10:1093-1095.
12. Gibaldi M, Perrier D. 1982. Pharmacokinetics. New York, NY: M. Dekker. Vol. 8, p. 494.
13. Huisman MT, Smit JW, Wiltshire HR, Hoetelmans RM, Beijnen JH, Schinkel AH. 2001. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Molecular Pharmacology 59:806-813.
14. Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T. 1993. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Research 53:4595-4602.
15. Jeong HY, Chiou WL. 2003. Rapid intestinal absorption mechanism of tacrolimus, a large molecule: Role of p-glycoprotein and lack of active uptake. AAPS Pharm Sci 5:W436.
16. Lan LB, Dalton JT, Schuetz EG. 2000. Mdr1 limits CYP3A metabolism in vivo. Molecular Pharmacology 58:863-869.
17. Lee HJ, Chiou WL. 1989. Erythrocytes as barriers for drug elimination in the isolated rat liver. I. Doxorubicin. Pharmacology Research 6:833-839.
18. Lin JH, Yamazaki M. 2003. Role of p-glycoprotein in pharmacokinetics: clinical implications. Clinical Pharmacokinetics 42:59-98.
19. Sparreboom A, Van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK, Borst P, Nooijen WJ, Beijnen JH, Van Tellingen O. 1997. Limited oral bioavailabiliry and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proceedings of the National Academy of Sciences, USA 94:2031-2035.
20. Takada K, Usuda H, Oh-Hashi M. 1992. Distribution kinetics of FK-506, a novel immunosuppressant, after intravenous administration to rats in comparison with cyclosporin A. Biopharmacology and Drug Disposition 13:345-355.
21. Thompson JA, Malkinson AM, Wand MD, Mastovich SL, Mead EW, Schullek KM, Laudenschlager WG. 1987. Oxidative metabolism of butylated hydroxytoluene by hepatic and pulmonary microsomes from rats and mice. Drug Metabolism and Disposition 15:833-840.
22. Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, McMichael J, Lever J, Burckart G, Starzl T. 1995. Clinical pharmacokinetics of tacrolimus. Clinical Pharmacokinetics 29:404-430.
23. Vincent SH, Karanam BV, Painter SK, Chiu SH. 1992. In vitro metabolism of FK-506 in rat, rabbit, and human liver microsomes: Identification of a major metabolite and of cytochrome P450 3A as the major enzymes responsible for its metabolism. Archives in Biochemistry and Biophysics 294:454-460.
24. Ward KW, Azzarano LM. 2004. Preclinical pharmacokinetic properties of the P-glycoprotein inhibitor GF120918A (HCl salt of GF120918, 9,10-dihydro-5- methoxy-9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl] phenyl]-4-acridine-carboxamide) in the mouse, rat, dog, and monkey. Journal of Pharmacology and Experimental Therapy 310:703-709.
25. Watanabe T, Miyauchi S, Sawada Y, Iga T, Hanano M, Inaba M, Sugiyama Y. 1992. Kinetic analysis of hepatobiliary transport of vincristine in perfused rat liver. Possible roles of P-glycoprotein in biliary excretion of vincristine. Journal of Hepatology 16:77-88.
26. Yokogawa K, Takahashi M, Tamai I, Konishi H, Nomura M, Moritani S, Miyamoto K, Tsuji A. 1999. P-glycoprotein-dependent disposition kinetics of tacrolimus: Studies in mdrla knockout mice. Pharmacology Research 16:1213-1218.